Angiosarcoma of the breast: a difficult surgical challenge.

Breast angiosarcoma presents following radiotherapy after breast conserving surgery, in the setting of chronic lymphoedema after axillary dissection or as a primary tumour. The Peter MacCallum Cancer Centre has significant experience due to large breast and sarcoma units and as a primary radiotherapy centre. Our aims were to evaluate the management and locoregional and distant outcomes after breast angiosarcoma.
Retrospective study of all patients from the prospective breast and sarcoma databases with a diagnosis of primary or secondary breast angiosarcoma at Peter MacCallum Cancer Centre was performed between January 2000 and December 2010. Mode of presentation, management, loco-regional recurrence and survival rates were reviewed.
Eight women developed angiosarcoma in the setting of breast conservation with a median latency of 7 years post radiotherapy. Six patients had primary breast angiosarcoma. All breast angiosarcomas were managed with total mastectomy with 5 patients requiring autologous tissue transfer. Four patients had adjuvant radiotherapy and three patients had adjuvant paclitaxel. The median follow-up was 2.5 years (6 month-10 years) with 7 episodes of local recurrence in four patients and 7 patients with distal metastases including two deaths from distant disease.
Primary angiosarcoma occurs de novo, presenting as a breast mass. Secondary angiosarcoma presents predominantly as a skin lesion, in the setting post-operative radiotherapy for breast conserving therapy. Angiosarcoma remains a rare and difficult management problem with poor loco-regional and distal control. Secondary AS is an iatrogenic condition that warrants close follow-up and judicial use of radiotherapy in breast conserving therapy.
AuthorsAaron Hui, Michael Henderson, David Speakman, Anita Skandarajah
JournalBreast (Edinburgh, Scotland) (Breast) Vol. 21 Issue 4 Pg. 584-9 (Aug 2012) ISSN: 1532-3080 [Electronic] Netherlands
PMID22305554 (Publication Type: Evaluation Studies, Journal Article)
CopyrightCrown Copyright © 2012. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Paclitaxel
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Breast Neoplasms (mortality, pathology, surgery, therapy)
  • Chemotherapy, Adjuvant
  • Female
  • Follow-Up Studies
  • Hemangiosarcoma (mortality, pathology, surgery, therapy)
  • Humans
  • Mastectomy
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Paclitaxel (therapeutic use)
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: